Physician profile
Michael M Parra
NPI 1063572493
$6,039.67
in general payments reported to CMS, 2019-2025
52 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $801 · 2021: $607 · 2022: $847 · 2023: $963 · 2024: $790 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $577.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $409.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $404.19 | 2019-2025 | |
| Amgen INC. | $371.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $353.73 | 2019-2025 | Airsupra, Farxiga, Evusheld |
| Bayer Healthcare Pharmaceuticals INC. | $289.64 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $288.70 | 2019-2023 | |
| Glaxosmithkline, LLC. | $246.99 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $240.64 | 2019-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $236.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.76 | 2019-2024 | Jardiance, Spiriva Respimat, Synjardy |
| Abbvie INC. | $205.51 | 2021-2025 | |
| Amarin Pharma, INC. | $191.48 | 2019-2020 | |
| Ardelyx, INC. | $139.47 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.50 | 2019-2023 | Xifaxan, Trulance |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Parra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.